GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » Interest Expense

Wakamoto Pharmaceutical Co (TSE:4512) Interest Expense : 円-1 Mil (TTM As of Sep. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Wakamoto Pharmaceutical Co's interest expense for the three months ended in Sep. 2024 was 円 0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was 円-1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Wakamoto Pharmaceutical Co's Operating Income for the three months ended in Sep. 2024 was 円 0 Mil. Wakamoto Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was 円 0 Mil. Wakamoto Pharmaceutical Co has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Wakamoto Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Wakamoto Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wakamoto Pharmaceutical Co Interest Expense Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.67 -0.57 -0.58 -0.58 -0.53

Wakamoto Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.10 -0.14 -0.15 -

Wakamoto Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wakamoto Pharmaceutical Co  (TSE:4512) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Wakamoto Pharmaceutical Co's Interest Expense for the three months ended in Sep. 2024 was 円0 Mil. Its Operating Income for the three months ended in Sep. 2024 was 円0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was 円0 Mil.

Wakamoto Pharmaceutical Co's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Wakamoto Pharmaceutical Co had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Wakamoto Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines